Increasing temperature accelerates Ti-6Al-4V oxide degradation and selective dissolution: An Arrhenius-based analysis.

Autor: Kurtz MA; Department of Bioengineering, Clemson University, Clemson, SC, USA; The Clemson University-Medical University of South Carolina Bioengineering Program, Charleston, SC, USA., Alaniz K; Department of Bioengineering, Clemson University, Clemson, SC, USA; The Clemson University-Medical University of South Carolina Bioengineering Program, Charleston, SC, USA., Taylor LM; Department of Bioengineering, Clemson University, Clemson, SC, USA; The Clemson University-Medical University of South Carolina Bioengineering Program, Charleston, SC, USA., Moreno-Reyes A; Department of Bioengineering, Clemson University, Clemson, SC, USA; The Clemson University-Medical University of South Carolina Bioengineering Program, Charleston, SC, USA., Gilbert JL; Department of Bioengineering, Clemson University, Clemson, SC, USA; The Clemson University-Medical University of South Carolina Bioengineering Program, Charleston, SC, USA. Electronic address: jlgilbe@clemson.edu.
Jazyk: angličtina
Zdroj: Acta biomaterialia [Acta Biomater] 2024 Apr 01; Vol. 178, pp. 352-365. Date of Electronic Publication: 2024 Feb 27.
DOI: 10.1016/j.actbio.2024.02.028
Abstrakt: Ti-6Al-4V selective dissolution occurs in vivo on orthopedic implants as the leading edge of a pitting corrosion attack. A gap persists in our fundamental understanding of selective dissolution and pre-clinical tests fail to reproduce this damage. While CoCrMo clinical use decreases, Ti-6Al-4V and the crevice geometries where corrosion can occur remain ubiquitous in implant design. Additionally, most additively manufactured devices cleared by the FDA use Ti-6Al-4V. Accelerated preclinical testing, therefore, would aid in the evaluation of new titanium devices and biomaterials. In this study, using temperature, we (1) developed an accelerated pre-clinical methodology to rapidly induce dissolution and (2) investigated the structure-property relationship between the dissolving surface and the oxide layer. We hypothesized that solution temperature and H 2 O 2 concentration would accelerate oxide degradation, increase corrosion kinetics and decrease experimental times. To assess this effect, we selected temperatures above (45 °C), below (24 °C), and at (37 °C) physiological levels. Then, we acquired electrochemical impedance spectra during active β dissolution, showing significant decreases in oxide polarization resistance (R p ) both over time (p = 0.000) and as temperature increased (p = 0.000). Next, using the impedance response as a guide, we quantified the extent of selective dissolution in scanning electron micrographs. As the temperature increased, the corrosion rate increased in an Arrhenius-dependent manner. Last, we identified three surface classes as the oxide properties changed: undissolved, transition and dissolved. These results indicate a concentration and temperature dependent structure-property relationship between the solution, the protective oxide film, and the substrate alloy. Additionally, we show how supraphysiological temperatures induce structurally similar dissolution to tests run at 37 °C in less experimental time. STATEMENT OF SIGNIFICANCE: Within modular taper junctions of total hip replacement systems, retrieval studies document severe corrosion including Ti-6AL-4V selective dissolution. Current pre-clinical tests and ASTM standards fail to reproduce this damage, preventing accurate screening of titanium-based biomaterials and implant designs. In this study, we induce selective dissolution using accelerated temperatures. Building off previous work, we use electrochemical impedance spectroscopy to rapidly monitor the oxide film during dissolution. We elucidate components of the dissolution mechanism, where oxide degradation precedes pit nucleation within the β phase. Using an Arrhenius approach, we relate these accelerated testing conditions to more physiologically relevant solution concentrations. In total, this study shows the importance of including adverse electrochemical events like cathodic activation and inflammatory species in pre-clinical testing.
Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests Dr. Jeremy Gilbert reports financial support was provided by Wyss Foundation. Dr. Jeremy Gilbert reports financial support was provided by DePuy Synthes. Dr. Jeremy Gilbert reports a relationship with Zimmer Biomet that includes: consulting or advisory. Dr. Jeremy Gilbert reports a relationship with Bausch and Lomb that includes: consulting or advisory. Dr. Jeremy Gilbert reports a relationship with Stryker Inc. that includes: consulting or advisory. Dr. Jeremy Gilbert reports a relationship with Corin/Omnilife Sciences and Naples Community Hospital that includes: consulting or advisory. Dr. Jeremy Gilbert reports a relationship with Smith and Nephew Inc that includes: consulting or advisory. Dr. Jeremy Gilbert reports a relationship with DePuy Synthes that includes: funding grants. Dr. Jeremy Gilbert reports a relationship with Bayer AG that includes: funding grants. Dr. Jeremy Gilbert reports a relationship with John Wiley & Sons Inc that includes: board membership. Dr. Jeremy Gilbert reports a relationship with Syracuse Bio-Materials Company LLC that includes: employment. Dr. Jeremy Gilbert reports a relationship with Society For Biomaterials that includes: board membership.
(Copyright © 2024 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: